Healthcare provider profile · identity verified

Stephanie A. Traxinger, DO

Family Practice · BISMARCK, ND · NPI 1366608465

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	516	119
Rosuvastatin Calcium	Rosuvastatin Calcium	503	131
Atorvastatin Calcium	Atorvastatin Calcium	417	98
Amlodipine Besylate	Amlodipine Besylate	400	100
Losartan Potassium	Losartan Potassium	384	98
Lisinopril	Lisinopril	265	73
Omeprazole	Omeprazole	244	59
Hydrochlorothiazide	Hydrochlorothiazide	228	56
Simvastatin	Simvastatin	207	52
Eliquis	Apixaban	187	29
Pantoprazole Sodium	Pantoprazole Sodium	184	51
Furosemide	Furosemide	159	40
Metoprolol Tartrate	Metoprolol Tartrate	159	29
Metoprolol Succinate	Metoprolol Succinate	147	36
Famotidine	Famotidine	138	40
Synthroid	Levothyroxine Sodium	132	30
Sertraline Hcl	Sertraline Hcl	129	29
Trazodone Hcl	Trazodone Hcl	129	33
Metformin Hcl	Metformin Hcl	122	29
Jardiance	Empagliflozin	98	17
Pravastatin Sodium	Pravastatin Sodium	97	24
Venlafaxine Hcl Er	Venlafaxine Hcl	96	20
Escitalopram Oxalate	Escitalopram Oxalate	92	22
Gabapentin	Gabapentin	91	26
Olmesartan Medoxomil	Olmesartan Medoxomil	91	19
Ezetimibe	Ezetimibe	83	19
Potassium Chloride	Potassium Chloride	83	24
Metformin Hcl Er	Metformin Hcl	82	17
Montelukast Sodium	Montelukast Sodium	77	20
Atenolol	Atenolol	73	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	73	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	68	17
Allopurinol	Allopurinol	66	14
Lorazepam	Lorazepam	63	19
Alendronate Sodium	Alendronate Sodium	62	16
Januvia	Sitagliptin Phosphate	62	suppressed
Alprazolam	Alprazolam	60	18
Citalopram Hbr	Citalopram Hydrobromide	59	13
Fluoxetine Hcl	Fluoxetine Hcl	57	suppressed
Paroxetine Hcl	Paroxetine Hcl	57	suppressed
Meloxicam	Meloxicam	54	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	53	12
Bupropion Xl	Bupropion Hcl	52	12
Oxybutynin Chloride	Oxybutynin Chloride	52	13
Tresiba Flextouch U-200	Insulin Degludec	52	suppressed
Fluticasone Propionate	Fluticasone Propionate	49	16
Xarelto	Rivaroxaban	49	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	47	suppressed
Rybelsus	Semaglutide	45	suppressed
Clopidogrel	Clopidogrel Bisulfate	44	suppressed
Duloxetine Hcl	Duloxetine Hcl	44	12
Celecoxib	Celecoxib	43	16
Pregabalin	Pregabalin	43	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	43	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	15
Fenofibrate	Fenofibrate	40	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	14
Albuterol Sulfate Hfa	Albuterol Sulfate	38	19
Myrbetriq	Mirabegron	38	suppressed
Donepezil Hcl	Donepezil Hcl	32	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	32	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	31	15
Fenofibrate	Fenofibrate Nanocrystallized	31	suppressed
Valacyclovir	Valacyclovir Hcl	31	17
Mirtazapine	Mirtazapine	30	suppressed
Solifenacin Succinate	Solifenacin Succinate	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Spironolactone	Spironolactone	26	suppressed
Topiramate	Topiramate	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	19
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	24	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	24	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	24	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	23	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Tramadol Hcl	Tramadol Hcl	22	11
Amoxicillin	Amoxicillin	21	13
Comfort Ez Pen Needle	Pen Needle, Diabetic	21	suppressed
Novolog Flexpen	Insulin Aspart	21	suppressed
Trulicity	Dulaglutide	21	suppressed
Ozempic	Semaglutide	20	suppressed
Farxiga	Dapagliflozin Propanediol	19	suppressed
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	17	suppressed
Propranolol Hcl	Propranolol Hcl	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	15
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Acyclovir	Acyclovir	14	suppressed
Irbesartan	Irbesartan	14	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	14	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	14	suppressed
Cefdinir	Cefdinir	13	suppressed
Flecainide Acetate	Flecainide Acetate	13	suppressed
Lubiprostone	Lubiprostone	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Ramipril	Ramipril	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	12
Benicar	Olmesartan Medoxomil	12	suppressed
Carvedilol	Carvedilol	12	suppressed
Diazepam	Diazepam	12	suppressed
Eszopiclone	Eszopiclone	12	suppressed
Glycopyrrolate	Glycopyrrolate	12	suppressed
Prednisone	Prednisone	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error